Impact of renin–angiotensin–aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: A prospective cohort study

2022
Written By CCRG CCRG Admin

Kei Sato, Nicole White, Jonathon P. Fanning, Nchafatso Obonyo, Michael H. Yamashita, Vinesh Appadurai, Anna Ciullo, Meryta May, Elliott T. Worku, Leticia Helms, Shinichiro Ohshimo, Dafsah A. Juzar, Jacky Y. Suen, Gianluigi Li Bassi, John F. Fraser, Rakesh C. Arora on behalf of COVID-19 Critical Care Consortium Investigators. BMC Cardiovasc Disord DOI 10.1186/s12872-022-02565-1

Background: The influence of renin–angiotensin–aldosterone system (RAAS) inhibitors on the critically ill COVID19 patients with pre-existing hypertension remains uncertain. This study examined the impact of previous use of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) on the critically ill COVID-19 patients.

CCRG CCRG Admin
Previous

In vivo evaluation of skin integration with ventricular assist device drivelines
Next

Coagulation Dysfunction in Acute Respiratory Distress Syndrome and Its Potential Impact in Inflammatory Subphenotypes